- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Understanding Drug Interactions in Systemic Treatment: Impact on Atopic Dermatitis Symptoms
Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.
EP: 1.Prevalence and QoL of Hand and Foot AD
EP: 2.Barrier Function and Atopic Dermatitis
EP: 3.Disease Severity's Influence on Atopic Dermatitis Therapeutic Selection
EP: 4.The AD Journey of a Construction Worker: Insights from a 38-Year-Old Caucasian Male
EP: 5.Empowering Patients: Effective Dermatologic Treatment Selection for Hand and Feet AD
EP: 6.Understanding Drug Interactions in Systemic Treatment: Impact on Atopic Dermatitis Symptoms
EP: 7.Practice Pearls for Optimizing the Management of Hand and Foot Atopic Dermatitis
This is a video synopsis of a discussion involving Alexandra Golant, MD, Assistant Professor at the Icahn School of Medicine at Mount Sinai, focusing on a case study of a 17-year-old African-American female with moderate to severe atopic dermatitis (AD), particularly affecting her hands and feet.
The patient, a student and waitress, has struggled with AD since childhood, experiencing persistent severe involvement despite various topical treatments, including topical calcineurin inhibitors and corticosteroids. Her occupation exacerbates her condition, with long periods of standing aggravating her foot symptoms, and visible hand lesions causing embarrassment in her customer service role.
Dr. Golant underscores the impact of AD on the patient's quality of life, especially during adolescence when self-confidence is developing. Given the failure of numerous topical treatments, Dr. Golant opts for a systemic approach, initiating dupilumab therapy due to its efficacy and favorable safety profile, even in combination with oral contraceptive pills and oral isotretinoin for acne.
Dupilumab's compatibility with other medications makes it a preferred choice, providing comprehensive disease control without significant drug interactions or adverse effects. Dr. Golant discusses the option of combining dupilumab with topical steroids for localized flare-ups, highlighting its safety and efficacy based on clinical trial data.
In summary, Dr. Golant's approach emphasizes tailoring treatment to the patient's individual needs, addressing both disease severity and psychosocial factors to improve overall well-being and treatment outcomes.
Video synopsis is AI-generated and reviewed by Dermatology Times®editorial staff.
